BLAINTRAVENOUS, SUBCUTANEOUSINJECTABLE1 Generic Approved
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
WEZLANA (ustekinumab-auub) by Amgen is interleukin-12 antagonists [moa]. Approved for interleukin-12 antagonist [epc]. First approved in 2023.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEZLANA (ustekinumab-auub) is a monoclonal antibody biosimilar to STELARA that blocks interleukin-12, a key cytokine driving inflammatory and autoimmune diseases. This IV/subcutaneous injectable targets the same IL-12 pathway as the reference product, offering an alternative for patients with plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The biosimilar pathway provides comparable efficacy to the originator with potential cost advantages.
Growth
Early-stage biosimilar in growth phase with opportunity to build market share against the peak-stage reference product STELARA; expect expanding commercial teams focused on payer access and formulary placement.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
WEZLANA is a growth-stage biosimilar with early career opportunity for professionals focused on payer access, formulary management, and adoption strategy against an entrenched reference product. Roles emphasize commercial execution, MSL education on biosimilar equivalence, and field sales to dermatologists, gastroenterologists, and rheumatologists.
Brand Manager
Worked on WEZLANA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.